MAFLD is characterized by elevated leptin and reduced adiponectin levels secondary to obesity and inflammation; early CKD shows an analogous pattern owing to diminished renal clearance, although adiponectin levels rise in later CKD stages. Here, ADIPOQ is linked to chronic kidney disease.